Navigation Links
Canandian Firm Announces Positive Results from Anti- Cervical Cancer Drug Trials

The Helix BioPharma Corporation has announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus (HPV)-induced low-grade cervical lesions.//

Human papilloma viruses (HPVs) are a large group of related viruses. They play a part in the development of cervical epithelial cancers. HPV is also associated with skin, oral and anal cancers.

Helix BioPharma Corporation is a Canada-based firm specializing in cancer therapies.

It says that its study showed a clinically efficacious response to the topical interferon treatment in nearly half of the treated patients. In addition, the product demonstrated an excellent safety profile, with no significant adverse side-effects.

Prof. Dr. Achim Schneider, a renowned expert in the field of cervical cancer and Director of the Department of Gynaecology at the Charité University Hospital in Berlin, said, . "Helix's product shows real promise as a practical and effective pharmaceutical means of preventing cervical cancer development in women affected by HPV-induced cervical lesions."

Twenty women received Topical Interferon Alpha-2b, self-administered intravaginally three times per week for a period of 6 weeks with a follow-up evaluation at 12 weeks, compared with 21 separately studied women who received no treatment whatsoever over the same study period.

Nearly half (46.7%) of the women in the treated population had their abnormal Pap smears revert to normal during the 12 week period, compared with only 15.8% of the untreated women (i.e., nearly a three-fold improvement).

In a PAP test cells from the cervix are collected for examination under a microscope. It is used to detect changes that may be cancer or may lead to cancer. It is named after George Papanicolaou, an American anatomist. "We are very pleased to have achieved this milestone in the continuing development of our Topical Inte rferon Alpha-2b product candidate," said John Docherty, Helix's Vice President of Corporate Development.

"Helix is committed to further advancing its clinical development program for this extremely prevalent condition, in order to bring this product to market as expeditiously as possible."

Interferon alpha-2b is an immune system modulator that is active against variety of HPV-induced lesions. Immune modulation is a new emerging field in the medical treatment of viral infections. It works by introducing an agent into the body that boosts specific areas of the immune system.

Interferon alpha-2b is thought to function by triggering an antiviral response within infected cells and by mobilizing the body's natural immune system to destroy the infected cells.

Helix's Topical Interferon Alpha-2b is expected to offer a safe, discreet, self-administered and pain-free therapy.
GP
'"/>




Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: